SE9601528D0 - Transdermally administered dextromethorphan as antitissue agent - Google Patents

Transdermally administered dextromethorphan as antitissue agent

Info

Publication number
SE9601528D0
SE9601528D0 SE9601528A SE9601528A SE9601528D0 SE 9601528 D0 SE9601528 D0 SE 9601528D0 SE 9601528 A SE9601528 A SE 9601528A SE 9601528 A SE9601528 A SE 9601528A SE 9601528 D0 SE9601528 D0 SE 9601528D0
Authority
SE
Sweden
Prior art keywords
antitissue
agent
transdermally administered
dextromethorphan
administered dextromethorphan
Prior art date
Application number
SE9601528A
Other languages
English (en)
Swedish (sv)
Inventor
Ulla Hoeck
Bo Kreilgaard
Helle Kristensen
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9601528A priority Critical patent/SE9601528D0/xx
Publication of SE9601528D0 publication Critical patent/SE9601528D0/xx
Priority to PCT/SE1997/000484 priority patent/WO1997039742A1/en
Priority to EP97915801A priority patent/EP0904067B1/de
Priority to AT97915801T priority patent/ATE284206T1/de
Priority to ES97915801T priority patent/ES2234012T3/es
Priority to NZ332215A priority patent/NZ332215A/xx
Priority to PT97915801T priority patent/PT904067E/pt
Priority to CA002251966A priority patent/CA2251966C/en
Priority to US09/171,674 priority patent/US6335030B1/en
Priority to DK97915801T priority patent/DK0904067T3/da
Priority to JP9537974A priority patent/JP2000509037A/ja
Priority to DE69731882T priority patent/DE69731882T2/de
Priority to AU23132/97A priority patent/AU714942B2/en
Priority to ZA9703444A priority patent/ZA973444B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SE9601528A 1996-04-23 1996-04-23 Transdermally administered dextromethorphan as antitissue agent SE9601528D0 (sv)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE9601528A SE9601528D0 (sv) 1996-04-23 1996-04-23 Transdermally administered dextromethorphan as antitissue agent
AU23132/97A AU714942B2 (en) 1996-04-23 1997-03-21 Transdermally administered dextromethorphan as antitussive agent
PT97915801T PT904067E (pt) 1996-04-23 1997-03-21 Dextrometorfan como agente antitussico administrado transdermicamente
EP97915801A EP0904067B1 (de) 1996-04-23 1997-03-21 Transdermal verabreichtes dextromethorphan als hustenmittel
AT97915801T ATE284206T1 (de) 1996-04-23 1997-03-21 Transdermal verabreichtes dextromethorphan als hustenmittel
ES97915801T ES2234012T3 (es) 1996-04-23 1997-03-21 Dextrometorfano administrado transdermicaente como agente antitusivo.
NZ332215A NZ332215A (en) 1996-04-23 1997-03-21 Transdermally administered dextromethorphan as antitussive agent
PCT/SE1997/000484 WO1997039742A1 (en) 1996-04-23 1997-03-21 Transdermally administered dextromethorphan as antitussive agent
CA002251966A CA2251966C (en) 1996-04-23 1997-03-21 Transdermally administered dextromethorphan as antitussive agent
US09/171,674 US6335030B1 (en) 1996-04-23 1997-03-21 Transdermally administered dextromethorphan as antitussive agent
DK97915801T DK0904067T3 (da) 1996-04-23 1997-03-21 Transdermalt indgivet dextromethorpan som hostestillende middel
JP9537974A JP2000509037A (ja) 1996-04-23 1997-03-21 鎮咳剤として経皮投与されるデキストロメトルファン
DE69731882T DE69731882T2 (de) 1996-04-23 1997-03-21 Transdermal verabreichtes dextromethorphan als hustenmittel
ZA9703444A ZA973444B (en) 1996-04-23 1997-04-22 Transdermally administered dextromethorphan as antitussive agents.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9601528A SE9601528D0 (sv) 1996-04-23 1996-04-23 Transdermally administered dextromethorphan as antitissue agent

Publications (1)

Publication Number Publication Date
SE9601528D0 true SE9601528D0 (sv) 1996-04-23

Family

ID=20402295

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9601528A SE9601528D0 (sv) 1996-04-23 1996-04-23 Transdermally administered dextromethorphan as antitissue agent

Country Status (14)

Country Link
US (1) US6335030B1 (de)
EP (1) EP0904067B1 (de)
JP (1) JP2000509037A (de)
AT (1) ATE284206T1 (de)
AU (1) AU714942B2 (de)
CA (1) CA2251966C (de)
DE (1) DE69731882T2 (de)
DK (1) DK0904067T3 (de)
ES (1) ES2234012T3 (de)
NZ (1) NZ332215A (de)
PT (1) PT904067E (de)
SE (1) SE9601528D0 (de)
WO (1) WO1997039742A1 (de)
ZA (1) ZA973444B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846495B2 (en) * 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
DE19901085C2 (de) * 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps
GB9920167D0 (en) * 1999-08-25 1999-10-27 Avery Dennison Corp Pressure sensitive adhesive compositions
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
US8133505B2 (en) * 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (en) * 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US7662404B2 (en) * 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
US7383084B2 (en) * 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US8502681B2 (en) * 2005-06-20 2013-08-06 Biovigil, Llc Hand cleanliness
JP5015620B2 (ja) * 2007-01-30 2012-08-29 株式会社クラレ 皮膚外用剤
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
EA201100984A1 (ru) 2008-12-19 2012-01-30 Грэйсуэй Фармасьютикалс, Ллс Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения актинического кератоза
EP2453747B1 (de) 2009-07-13 2017-08-30 Medicis Pharmaceutical Corporation Imiquimod-formulierungen mit geringerer dosisstärke und kurze dosierpläne zur behandlung von warzen im genital- und perianalbereich
US8461102B2 (en) * 2010-03-02 2013-06-11 George E. Royster, JR. Methods and compositions for treating and preventing symptoms of hormonal variations
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
TWI795446B (zh) * 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
EP4125902A4 (de) * 2020-03-30 2024-05-22 Shinkei Therapeutics, Inc. Transdermale verabreichung von dextromethorphan
CN117545474A (zh) 2021-11-08 2024-02-09 李维庸 一种用于向患者递送药物的透皮给药系统

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275510A (en) * 1966-09-27 Topical antitussive preparations
US2676177A (en) 1949-11-09 1954-04-20 Hoffmann La Roche Process for the preparation of optically active 3-methoxy-n-methyl morphinans and salts thereof
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
JPS6351327A (ja) * 1986-08-22 1988-03-04 Sato Seiyaku Kk 液状組成物
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US4888354A (en) 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US4915950A (en) 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5164406A (en) 1988-06-02 1992-11-17 Bristol-Myers Squibb Co. Method for enhancing transdermal penetration and compositions useful therein
EP0351897A3 (de) 1988-06-17 1990-03-21 The Procter & Gamble Company Hautpenetrierendes System für aminfunktionelle Anrzneistoffsalze
WO1991015261A1 (en) * 1990-03-30 1991-10-17 Medtronic, Inc. Activity controlled electrotransport drug delivery device
US5213568A (en) 1990-03-30 1993-05-25 Medtronic Inc. Activity controlled electrotransport drug delivery device
PL168968B1 (en) 1990-10-31 1996-05-31 Procter & Gamble Method of manufacturing an antitussive drug
GB9103302D0 (en) * 1991-02-16 1991-04-03 Smithkline Beecham Plc Pharmaceutical formulations
EP0608320B1 (de) 1991-10-16 1998-01-28 Richardson-Vicks, Inc. Verbesserte hautpenetrationssysteme fuer erhoehte topische freisetzung von arzneimitteln
EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
US5260066A (en) 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
US5756117A (en) * 1992-04-08 1998-05-26 International Medical Asscociates, Inc. Multidose transdermal drug delivery system
CA2169729C (en) 1993-08-19 2001-04-03 James E. Biegajski Water-soluble pressure-sensitive mucoadhesive

Also Published As

Publication number Publication date
EP0904067B1 (de) 2004-12-08
DE69731882D1 (de) 2005-01-13
US6335030B1 (en) 2002-01-01
NZ332215A (en) 2000-09-29
DE69731882T2 (de) 2005-12-15
AU2313297A (en) 1997-11-12
PT904067E (pt) 2005-02-28
ZA973444B (en) 1997-11-18
CA2251966A1 (en) 1997-10-30
ES2234012T3 (es) 2005-06-16
AU714942B2 (en) 2000-01-13
JP2000509037A (ja) 2000-07-18
CA2251966C (en) 2008-01-15
DK0904067T3 (da) 2005-03-14
WO1997039742A1 (en) 1997-10-30
EP0904067A1 (de) 1999-03-31
ATE284206T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
SE9601528D0 (sv) Transdermally administered dextromethorphan as antitissue agent
NZ508526A (en) Opioid formulations for treating pain
NO931766D0 (no) Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin
CA2341063A1 (en) Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
GR3032523T3 (en) Therapeutic preparation for the transdermal administration of active substances
ES2137261T3 (es) Administracion transdermica de oxibutinina.
WO2001013909A3 (en) Compositions and methods for treating opiate intolerance
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
NO993385D0 (no) Transdermalt terapeutisk system for avgivelse av hormoner
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
DK0538302T3 (da) Reduktion eller forhindring af hudirritation forårsaget af lægemidler
DK0754034T3 (da) Brusende farmaceutiske formuleringer indeholdende biologisk nedbrydelige mikrokapsler med kontrolleret afgivelse
PT1003477E (pt) Sistema terapeutico transdermico (tts), contendo polimeros de (met)acrilato com grupos amonio para administracao de levonorgestrel
ATE388687T1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi
HK1038310A1 (en) Compositions and methods for treating intracellular infections.
MY124465A (en) Reduction of infarct volume using citicoline
SE9601527D0 (sv) Transdermally alministered acetylcysteine as mucolytic agent
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
ATE81775T1 (de) Pharmazeutische zusammensetzungen.
ATE280575T1 (de) Transdermales therapeutisches system zur anwendung von candesartan
GR900100489A (el) Συνθέσεις χρήσιμοι ως αντισυλληπτικά για άνδρες.
EP0906757A3 (de) Analgetische Zusammensetzung welche Moxonidine und ein Opioid-Analgetika enthält
DK408188D0 (da) Injicerbart middel til kontrolleret frigivelse af opioid-analgetika
MX9604426A (es) Reduccion de irritacion de la piel durante el surtido por electrotransporte.